JP2021513963A - 異常増殖性疾患を治療するための薬剤および方法 - Google Patents

異常増殖性疾患を治療するための薬剤および方法 Download PDF

Info

Publication number
JP2021513963A
JP2021513963A JP2020543209A JP2020543209A JP2021513963A JP 2021513963 A JP2021513963 A JP 2021513963A JP 2020543209 A JP2020543209 A JP 2020543209A JP 2020543209 A JP2020543209 A JP 2020543209A JP 2021513963 A JP2021513963 A JP 2021513963A
Authority
JP
Japan
Prior art keywords
alkyl
compound
compound according
cancer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020543209A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019161345A5 (https=
JP2021513963A5 (https=
Inventor
フカセ，ヨシユキ
ダガン，マーク
ウェンデル，ハンス−グイド
シン，カミニ
Original Assignee
メモリアル スローン ケタリング キャンサー センター
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, メモリアル スローン ケタリング キャンサー センター filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2021513963A publication Critical patent/JP2021513963A/ja
Publication of JPWO2019161345A5 publication Critical patent/JPWO2019161345A5/ja
Publication of JP2021513963A5 publication Critical patent/JP2021513963A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
JP2020543209A 2018-02-19 2019-02-18 異常増殖性疾患を治療するための薬剤および方法 Pending JP2021513963A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862632372P 2018-02-19 2018-02-19
US62/632,372 2018-02-19
PCT/US2019/018441 WO2019161345A1 (en) 2018-02-19 2019-02-18 Agents and methods for treating dysproliferative diseases

Publications (3)

Publication Number Publication Date
JP2021513963A true JP2021513963A (ja) 2021-06-03
JPWO2019161345A5 JPWO2019161345A5 (https=) 2022-03-01
JP2021513963A5 JP2021513963A5 (https=) 2022-03-01

Family

ID=67619605

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020543209A Pending JP2021513963A (ja) 2018-02-19 2019-02-18 異常増殖性疾患を治療するための薬剤および方法

Country Status (9)

Country Link
US (2) US12215090B2 (https=)
EP (1) EP3755693B1 (https=)
JP (1) JP2021513963A (https=)
KR (1) KR20200123184A (https=)
CN (1) CN112351977A (https=)
AU (1) AU2019221837B2 (https=)
CA (1) CA3091642A1 (https=)
IL (1) IL276639A (https=)
WO (1) WO2019161345A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113149942B (zh) * 2021-02-10 2023-06-02 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种洛克米兰醇酚羟基衍生物、其制备方法和应用
WO2022221519A1 (en) * 2021-04-14 2022-10-20 Memorial Sloan-Kettering Cancer Center Synthetic rocaglates with broad-spectrum antiviral activities and uses thereof
CN121712777A (zh) * 2023-08-18 2026-03-20 皇家学术促进机构麦吉尔大学 Rna解旋酶抑制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139749A2 (en) * 2006-05-22 2007-12-06 Trustees Of Boston University Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids
WO2011140334A2 (en) * 2010-05-06 2011-11-10 Trustees Of Boston University Compounds, methods of making or identifying compounds, and uses thereof
JP2017519796A (ja) * 2014-07-04 2017-07-20 ピエール、ファーブル、メディカマン フラバグリン誘導体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19934952A1 (de) * 1998-07-30 2000-02-03 Novartis Ag Cyclopentabenzofuran-Derivate
AUPQ866500A0 (en) 2000-07-05 2000-08-03 Exgenix Operations Pty Ltd Therapeutic compounds and methods
US7816544B2 (en) 2004-03-23 2010-10-19 Trustees Of Boston University Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species
DE102004024504A1 (de) 2004-05-18 2006-02-16 Bayer Healthcare Ag Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
WO2006007634A1 (en) 2004-07-16 2006-01-26 Cerylid Biosciences Ltd Processes and intermediates
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
EP2189158A1 (en) 2008-11-20 2010-05-26 DKFZ Deutsches Krebsforschungszentrum, Stiftung des Öffentlichen Rechts Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer
EP2189453A1 (en) 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglaol derivatives as cardioprotectant agents
US20140255432A1 (en) 2011-07-27 2014-09-11 Ohio State Innovation Foundation Silvestrol, silvestrol analogs and uses thereof
WO2013170257A1 (en) 2012-05-11 2013-11-14 Dana-Farber Cancer Institute, Inc. Treating muc1-expressing cancers with helicase inhibitors
WO2015085221A2 (en) 2013-12-05 2015-06-11 Memorial Sloan Kettering Cancer Center Methods for identifying anti-cancer compounds
JP6306481B2 (ja) 2014-03-17 2018-04-04 株式会社神戸製鋼所 延性及び曲げ性に優れた高強度冷延鋼板および高強度溶融亜鉛めっき鋼板、並びにそれらの製造方法
EP3888658B1 (en) * 2015-11-25 2023-12-27 Effector Therapeutics, Inc. Eif4-a-inhibiting compounds and methods related thereto
US10639378B2 (en) * 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139749A2 (en) * 2006-05-22 2007-12-06 Trustees Of Boston University Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids
WO2011140334A2 (en) * 2010-05-06 2011-11-10 Trustees Of Boston University Compounds, methods of making or identifying compounds, and uses thereof
JP2017519796A (ja) * 2014-07-04 2017-07-20 ピエール、ファーブル、メディカマン フラバグリン誘導体

Also Published As

Publication number Publication date
US20200392099A1 (en) 2020-12-17
US12215090B2 (en) 2025-02-04
EP3755693A4 (en) 2021-08-04
AU2019221837B2 (en) 2024-08-01
IL276639A (en) 2020-09-30
WO2019161345A1 (en) 2019-08-22
AU2019221837A1 (en) 2020-09-03
KR20200123184A (ko) 2020-10-28
CN112351977A (zh) 2021-02-09
CA3091642A1 (en) 2019-08-22
EP3755693A1 (en) 2020-12-30
EP3755693B1 (en) 2024-06-12
US20250361218A1 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
CN105646389B (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途
CN112566900B (zh) 免疫调节剂及其组合物和制备方法
JP2021054856A (ja) トリアジン化合物及びその医薬用途
JP2020502103A (ja) Ｃｆｔｒ増強物質としての二環式ヘテロアリール誘導体
JP2017520612A (ja) 抗がん剤としての官能化され置換されたインドール
JP2019513743A (ja) インドールアミン ２，３−ジオキシゲナーゼ阻害剤、その製造方法及び応用
US20250361218A1 (en) Agents and methods for treating dysproliferative diseases
WO2012136111A1 (zh) 苯丙酸化合物、其制备方法及其医药用途
JP7778750B2 (ja) ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態
CN114008028A (zh) 抑制癌细胞生长的嘧啶衍生物及其医药用途
CN112321568B (zh) 4-甲基吡咯取代的吲哚酮衍生物、其制备方法及其医药用途
WO2006077901A1 (ja) Ctgf発現阻害剤
JP7531506B2 (ja) アクリル含有核輸送モジュレーターおよびその使用
JP4958379B2 (ja) １−［アルキル］，１−［（ヘテロアリール）アルキル］および１−［（アリール）アルキル］−７−ピリジニル−イミダゾ［１，２−ａ］ピリミジン−５（１Ｈ）−オン誘導体
CN102807575B (zh) 3-芳基-5-噻吩基-5H-噻唑并[3,2-a]嘧啶类衍生物及其应用
JP5378499B2 (ja) 微小管形成阻害剤として有用なベンゾフェノンチアゾール誘導体及びその製造方法
WO2021129841A1 (zh) 用作ret激酶抑制剂的化合物及其应用
US10093609B2 (en) TAK1 kinase inhibitors, compositions, and uses related thereto
WO2015074124A1 (en) Functionalised and substituted indoles as anti-cancer agents
JP2003128548A (ja) 縮合イミダゾリウム誘導体を含む医薬組成物
JP7025542B2 (ja) Ｔｇｆ－ベータ阻害剤としてのオキサジアゾール及びチアジアゾール
WO2022068815A1 (zh) Fxr小分子激动剂及其制备方法和用途
JP5735122B2 (ja) 抗癌活性を有するベンズアミド誘導体並びにその製造方法および使用
WO2022167962A1 (en) Substituted pyrazolyl compounds as malt-1 inhibitors
WO2017098733A1 (ja) インドール酢酸誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230515

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230921